BD Port Access Kits
Carousel Image
Loading
tabs dropdown arrow
Overview
  • Designed to standardize port access procedures
  • Provides the convenience of necessary kit components in a common package
  • Kit components are organized to facilitate sterile "best practices" for port access related procedures
  • Assists clinicians in complying with guidelines for sterile port access outlined by nursing societies and the CDC
  • Procedural Checklist included in every kit:
    • Educate and assist in sterile port access technique
    • Convenient documentation and tracking of port access procedure
    • Procedural checklist for simplified protocol documentation
true

Port Access Related Implications

An estimated 3-6% of ports placed will develop a port-related infection, impacting a cancer patient’s already challenging treatment.1, 2, 3, 4, 5 Port-related infections may be due to the initial access or in-dwell of an infusion set in the patient’s port.

For the patient:

  • Port removal
  • Chemotherapy/treatment interruption
  • Hospital in-patient stay
  • Secondary complications from infection
  • Placement of a 2nd device that may not offer the benefits of a port

For the facility:

  • Port removal
  • Potential hospital stay
  • Additional procedures and devices
  • Less or lack of reimbursement due to recent CMS changes regarding central line infections

Proper Port-Access Technique Matters

Nearly 80% of Oncology Nurses surveyed by BD cite poor sterile technique, site prep or access procedures as the likely cause for port access related infections.†

Help clinicians to meet the following:

  • Centers for Disease Control (CDC) Guidelines
  • Infusion Nursing Society (INS) Standards of Practice
  • Oncology Nursing Society (ONS) Guidelines
  • Occupational Safety & Health Administration (OSHA) Guidelines
  • The Joint Commission (JCAHO) National Patient Safety Goals

Features and Benefits

BD Port Access Kit available in the following safety infusion set configurations:

  • MiniLoc™ Safety Infusion Set
  • SafeStep™ Huber Needle Set
  • PowerLoc™ Safety Infusion Set
  • PowerLoc™ Max Safety Infusion Set
Reference
  • Vescia, S. et al., Management of Venous Port Systems in Oncology: A review of current evidence, Annals of Oncology, Sept 2007, 19:9-15.
  • Groeger, Jeffrey S. et.al., Infectious Morbidity Associated with Long-Term Use of Venouos Access Devices in Patients with Cancer, Annals of Internal Medicine, 1993; 119:1168-1174.
  • Grannan, Kevin I., et.al., Early and Late Complications of Totally Implantable Venous Access Devices, Journal of Surgical Oncology, 1990, 44:52-54.
  • Pegeus, David, et.al., Comparison of Infections in Hickman and Implanted Port Catheters in Adult Solid Tumor Patients, Journal of Surgical Oncology, 49: 156-162 (1992).
  • Groeger, Jeffrey S. et.al., Venous Access in the Cancer Patient, Principles and Practice of Oncology, 1991; vol. 5 no. 3

† Survey results on file at C. R. Bard, Inc.

Please consult product labels, IFU, and package inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use.

true
Products & Accessories
  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 22 G x 1.5"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 22 G x 1.5"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 22 G x .75"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 22 G x .75"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 19 G x 1.5"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 19 G x 1.5"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 22 G x .75"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 19 G x .75"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 20 G x .75"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 22 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 22 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 22 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 19 G x .75"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 19 G x .75"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 20 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 20 G x 1.5"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 20 G x 1.5"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 20 G x .75"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 20 G x .75"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 19 G x 1.5"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 19 G x 1"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 20 G x 1.5"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 19 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 19 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK, 20 G x 1"

  • product-image

    PowerLoc® MAX Power-Injectable Infusion Set PAK with Y-Injection Site, 20 G x 1"

  • product-image

    PowerLoc® Safety Infusion Set PAK with Y-Injection Site, 22 G x 1.5"

References
  • Vescia, S. et al., Management of Venous Port Systems in Oncology: A review of current evidence, Annals of Oncology, Sept 2007, 19:9-15.
  • Groeger, Jeffrey S. et.al., Infectious Morbidity Associated with Long-Term Use of Venouos Access Devices in Patients with Cancer, Annals of Internal Medicine, 1993; 119:1168-1174.
  • Grannan, Kevin I., et.al., Early and Late Complications of Totally Implantable Venous Access Devices, Journal of Surgical Oncology, 1990, 44:52-54.
  • Pegeus, David, et.al., Comparison of Infections in Hickman and Implanted Port Catheters in Adult Solid Tumor Patients, Journal of Surgical Oncology, 49: 156-162 (1992).
  • Groeger, Jeffrey S. et.al., Venous Access in the Cancer Patient, Principles and Practice of Oncology, 1991; vol. 5 no. 3

† Survey results on file at C. R. Bard, Inc.

Please consult product labels, IFU, and package inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use.

true
Resources
References
  • Vescia, S. et al., Management of Venous Port Systems in Oncology: A review of current evidence, Annals of Oncology, Sept 2007, 19:9-15.
  • Groeger, Jeffrey S. et.al., Infectious Morbidity Associated with Long-Term Use of Venouos Access Devices in Patients with Cancer, Annals of Internal Medicine, 1993; 119:1168-1174.
  • Grannan, Kevin I., et.al., Early and Late Complications of Totally Implantable Venous Access Devices, Journal of Surgical Oncology, 1990, 44:52-54.
  • Pegeus, David, et.al., Comparison of Infections in Hickman and Implanted Port Catheters in Adult Solid Tumor Patients, Journal of Surgical Oncology, 49: 156-162 (1992).
  • Groeger, Jeffrey S. et.al., Venous Access in the Cancer Patient, Principles and Practice of Oncology, 1991; vol. 5 no. 3

† Survey results on file at C. R. Bard, Inc.

Please consult product labels, IFU, and package inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use.

true

Kit Components

Description Kit
Your Preferred Bard® Huber Needle 1
Syringe, Sodium Chloride (Saline) 0.9%, 10mL 1
Dressing, Transparent 1
Gauze Pad, 2 in. x 2 in. 4
Gloves, Non-Latex, Sterile 2
Procedure Checklist 1
Mask 1
Prep Pad, Alcohol 1
Prep Pad, Skin Protectant 1
Tape Strips, Anchor (3 per) 1
Towel, Absorbent 1
Dressing Change Label 1
Reference
  • Vescia, S. et al., Management of Venous Port Systems in Oncology: A review of current evidence, Annals of Oncology, Sept 2007, 19:9-15.
  • Groeger, Jeffrey S. et.al., Infectious Morbidity Associated with Long-Term Use of Venouos Access Devices in Patients with Cancer, Annals of Internal Medicine, 1993; 119:1168-1174.
  • Grannan, Kevin I., et.al., Early and Late Complications of Totally Implantable Venous Access Devices, Journal of Surgical Oncology, 1990, 44:52-54.
  • Pegeus, David, et.al., Comparison of Infections in Hickman and Implanted Port Catheters in Adult Solid Tumor Patients, Journal of Surgical Oncology, 49: 156-162 (1992).
  • Groeger, Jeffrey S. et.al., Venous Access in the Cancer Patient, Principles and Practice of Oncology, 1991; vol. 5 no. 3

† Survey results on file at C. R. Bard, Inc.

Please consult product labels, IFU, and package inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use.

true
Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×